Abaco Capital (OXP)

 

Latest News

Oxford Pharmascience completes demerger

Oxford Pharmascience Group confirmed that it has completed the Demerger, under which certain operating and other as...

Completion of Demerger

RNS Number: 0617A Oxford Pharmascience Group PLC 21 December 2017 Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company" and, together with its subsidiaries, the " Group") Completion of Demerger, Board Changes & Change of Company Name to Abaco Capital plc Unless otherwise indicated, capitalised terms in this announcement ha...

Confirmation of Capital Reductions

RNS Number: 8390Z Oxford Pharmascience Group PLC 19 December 2017 Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company") Confirmation of Capital Reductions Unless otherwise indicated, capitalised terms in this announcement have the meaning given to them in the definitions appearing in the circular issued by the Company on 10 N...

Oxford Pharmascience completes capital subdivision

Oxford Pharmascience Group said it has now completed the subdivision of its capital whereby each Existing Share of 0.00...

All News

DateHeadlineSource
21-12-17Oxford Pharmascience completes demergerStockMarketWire
21-12-17Completion of DemergerRNS
19-12-17Confirmation of Capital ReductionsRNS
04-12-17Oxford Pharmascience completes capital subdivisionStockMarketWire
04-12-17Subdivision of CapitalRNS
29-11-17Oxford Pharmascience gets FDA adviceStockMarketWire
29-11-17FDA Advice on OXPzero Ibuprofen OTC OpportunityRNS
27-11-17All resolutions passed at GM of Oxford PharmascienceStockMarketWire
27-11-17Result of General MeetingRNS
22-11-17Holding(s) in CompanyRNS
22-11-17Holding(s) in CompanyRNS
20-11-17Second Price Monitoring ExtnRNS
20-11-17Price Monitoring ExtensionRNS
20-11-17MPA Advice on OXPzeroT Ibuprofen OTC OpportunityRNS
10-11-17Oxford Pharmascience proposes demergerStockMarketWire
10-11-17Announcement of demergerRNS
02-10-17OXP receives MHRA advice on OXPzeroStockMarketWire
02-10-17MHRA Advice on OXPzeroT Ibuprofen OTC OpportunityRNS
25-09-17Interim ResultsRNS
19-06-17All resolutions passed at AGM of Oxford PharmascienceStockMarketWire
19-06-17Result of AGMRNS
08-06-17Further Update re: OXPzero Ibuprofen ProgrammesRNS
09-05-17Update regarding OXPzeroTM Ibuprofen ProgrammesRNS
31-03-17Miners drag on FTSE as commodity prices fall StockMarketWire
31-03-17Second Price Monitoring ExtnRNS
31-03-17FTSE falls on miners, financials as Old Mutual suffersStockMarketWire
31-03-17Price Monitoring ExtensionRNS
31-03-17Oxford Pharmascience disappointed with FDA feedbackStockMarketWire
31-03-17FDA Feedback on OXPzeroT Ibuprofen Rx ProgrammeRNS
10-03-17Oxford Pharmascience narrows FY pretax lossStockMarketWire
10-03-17Final ResultsRNS
07-03-17Notice of ResultsRNS
23-02-17Company UpdateRNS
25-01-17Oxford Pharmascience - Company updateBRR Media
17-01-17Oxford Pharmascience issues company updateStockMarketWire
17-01-17Company UpdateRNS
09-11-16R&D UpdateRNS
19-10-16Here's what Neil Woodford is buying and sellingInteractive Investor
13-09-16Oxford Pharmascience - Interim results 2016BRR Media
07-09-16Interim results for the 6 months to 30 June 2016RNS

RSS feeds

  • Editorial news feed for LSE:OXP Editorial
  • Regulatory news feed for LSE:OXP Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account